Kura Oncology Inc

NASDAQ KURA

Download Data

Kura Oncology Inc Gross Profit Per Share 1 year YoY Change (%) for the quarter ending March 31, 2024: 7.39%

Kura Oncology Inc Gross Profit Per Share 1 year YoY Change (%) is 7.39% for the quarter ending March 31, 2024. Gross Profit per Share represents the gross profit allocated to each outstanding share of common stock. It provides insight into the per-share value of gross profit and is commonly used in valuation analysis. A higher value suggests a potentially more favorable investment opportunity. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Kura Oncology Inc Gross Profit Per Share for the quarter ending March 31, 2023 was -0.00.
NASDAQ: KURA

Kura Oncology Inc

CEO Dr. Troy Edward Wilson J.D., Ph.D.
IPO Date Sept. 22, 2015
Location United States
Headquarters 12730 High Bluff Drive, San Diego, CA, United States, 92130
Employees 142
Sector Healthcare
Industry Biotechnology
Description

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Similar companies

REPL

Replimune Group Inc

NA

NA

KALV

Kalvista Pharmaceuticals Inc

NA

NA

THRX

Theseus Pharmaceuticals Inc

NA

NA

GRCL

Gracell Biotechnologies Inc.

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

COGT

Cogent Biosciences Inc

NA

NA

DAWN

Day One Biopharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email